Patients treated for their prolonged seizures with the sedative propofol may be at high risk for complications and even death. New research presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), shows that the use of propofol as an antiepileptic agent in patients with refractory status epilepticus (RSE), prolonged seizures...

The importance of a new archeological site in St George, Utah, U.S. was recently highlighted by Andrew Milner, Paleontologist, City of St. George, Jim Kirkland, State Paleontologist and Sidney Ash, Paleo-botanists. The site is significant because it is the only early Jurassic land flora known in the western United States.  It provides evidence that a variety of land plants were present in the...

Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT), funded by the National Cancer Institute (NCI) and other institutes that comprise the National Institutes of Health shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer. The data also showed two concerning trends: a small but not stati...

People who take bisphosphonates for osteoporosis may be at risk for serious atrial fibrillation (AF), or irregular heartbeats, according to a new study. The research, presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), shows that people taking alendronate or zoledronic acid, two common medications to prevent or slow the occ...

Seven years after Sept. 11, and in the wake of many major natural disasters such as forest fires, hurricanes and flooding, nearly half of U.S. states either have no state-level emergency plan or do not provide it readily to the public, reveals a new study by George Mason University Communication Professor Carl Botan. Despite federal laws that require a state emergency operations plan (EOP) as a pr...

Preliminary trials of a new multi-kinase inhibitor have indicated it has impressive tumour shrinkage activity in patients with a difficult to treat type of thyroid cancer. The results have put the drug`s development on a fast track, prompting the accelerated initiation of a large phase III trial. The compound, XL184, targets cell growth and migration, as well as blood vessel growth (angiogenesis),...